Document is current
Any future updates will be listed below
-
Authors
Kokolakis, Evangelos
von Mücke-Heim, Iven-Alex
Pape, Julius C.
Grandi, Norma C.
Erhardt, Angelika
Sämann, Philipp G.
Spoormaker, Victor
Gogolla, Nadine
Binder, Elisabeth B.
Falkai, Peter
-
Funding
Funding for this research was provided by:
Max Planck Institute of Psychiatry
- License Information
-
More Information
Article History
Received: 23 November 2025
Accepted: 25 February 2026
First Online: 2 March 2026
Competing interests
: EK nothing to disclose. I-AMH nothing to disclose. JP nothing to disclose. NG nothing to disclose. AE nothing to disclose. PGS nothing to disclose. VS: patent applications PCT/EP2024/071376 and PCT/EP2024/071377, consultancy for Roche, Sony, Boehringer-Ingelheim, co-founder of Biomentric UG (entrepreneurial company), equity in Biomentric UG. EB nothing to disclose. NG nothing to disclose. PF gives payed talks and is partly a member of the advisory board at BMS, Richter, Johnson and Johnson and Otsuka.
